KalVista Q4 2023 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for Q4 2023. The company's net loss was $26.3 million, or $(0.77) per share. Research and development expenses were $24.0 million, and general and administrative expenses were $7.8 million. The company's cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023. Target enrollment was achieved for the sebetralstat phase 3 KONFIDENT trial and data readout is expected in Q4.
Target enrollment achieved for sebetralstat phase 3 KONFIDENT trial.
Data readout from KONFIDENT trial expected in Q4 2023.
NDA submission planned for H1 2024.
Company funded into 2025.
KalVista
KalVista
Forward Guidance
KalVista expects data from the event-driven KONFIDENT trial in the fourth quarter of 2023 and, if successful, anticipates submitting an NDA to the FDA in the first half of 2024. With the financing, KalVista now expects to be able to fund operations into 2025.
Positive Outlook
- Data readout from KONFIDENT trial expected in Q4 2023.
- NDA submission planned for H1 2024.
- Company funded into 2025.